Q4 2025 · 13F-HR
Fairmount Funds Management LLCholdings as filed
Filed 2026-02-17 · accession 0001104659-26-016303
$1.31B
Reported value
13
Positions
2025-12-31
Period end
The Brief · Fairmount Funds Management LLC · Q4 2025
AI · grounded in 13F
Fairmount Funds Management LLC closed its position in AXSM, reducing its exposure by $99.0M. The fund also exited positions in SRRK and ABVX, totaling losses of $67.9M and $60.6M respectively. On the buy side, the fund increased its stake in Crescent Biopharma Inc. by 97.99% and accumulated more shares of JBIO by 41.4%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $319.8M | 24.3% | 9,003,418 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $154.6M | 11.8% | 2,048,647 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $131.6M | 10.0% | 4,018,101 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $121.8M | 9.27% | 3,914,458 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $112.3M | 8.55% | 3,705,262 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $88.1M | 6.70% | 2,137,191 | Common | SOLE |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $80.2M | 6.11% | 2,209,025 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $73.2M | 5.57% | 727,563 | Common | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $70.3M | 5.35% | 4,553,494 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $57.2M | 4.35% | 3,711,444 | Common | SOLE |
| G52694109 | KNSA | KINIKSA PHARMACEUTICALS INTL | $54.4M | 4.14% | 1,319,688 | Common | SOLE |
| G2545C104 | CBIO | CRESCENT BIOPHARMA INC. | $32.6M | 2.48% | 2,747,866 | Common | SOLE |
| 45719W205 | IKT | INHIBIKASE THERAPEUTICS INC | $17.7M | 1.35% | 8,625,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.